What Genoskin does

Genoskin is a French-headquartered biotechnology contract research organization (CRO) that develops and supplies ex vivo human skin models as alternatives to animal testing for pharmaceutical, biotechnology, medical device, cosmetics, and chemicals customers. The company's core technology is a proprietary, patented process that keeps donated human skin alive for up to seven days post-surgery, preserving all cell types and skin structures so that drug developers can perform a full week of testing on living, immunocompetent human tissue rather than animal models or reconstructed epidermis.

The product portfolio comprises standardized ready-to-use platforms — NativeSkin (live full-thickness human skin), HypoSkin (subcutaneous injection testing), InflammaSkin (psoriasis/inflammatory model), WoundSkin (wounded skin for healing and infection studies), HairSkin and FacialSkin (facial-surgery-derived tissue), FrozenSkin, HistoSkin (FFPE sections), proprietary culture medium, and human primary mast cells — supplemented by a services layer including non-clinical toxicity studies (ISR Platform), local tolerance studies, vaccine immunoprofiling, topical/transdermal testing, spatial biology (Mantis), and bioinformatics analysis.

Revenue is generated through three streams: (i) one-time unit sales of standardized skin models and skin derivatives via three regional e-commerce storefronts (US, EU/Middle East, APAC) priced between roughly $99 and $1,250 per unit, (ii) custom non-clinical research services priced via bespoke study plans with 50% initiation payments and rapid 2-week study initiation, and (iii) ancillary sales of mast cells and proprietary culture medium. The company operates from Toulouse, France (HQ) and Salem, Massachusetts (US operations), serves 490+ customers with 75% of the top 20 large pharma companies already partnered, and has produced 90+ peer-reviewed publications using its models.

Name

Genoskin

Legal name

GENOSKIN SAS

Website

https://genoskin.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Genoskin is a French-headquartered biotech CRO that provides ex vivo human skin models and custom non-clinical research services as human-relevant, animal-testing alternatives to pharmaceutical, biotech, medical device, cosmetics, and chemicals customers across North America, Europe, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

akta.pro secondary industries

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Ex vivo skin models
• Preclinical CRO services
• Animal testing alternatives
• Human skin biology
• Drug safety testing

Headquarters

HQ city

Toulouse

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Skin Model Products: Sale of standardized and custom ex vivo human skin models (NativeSkin, HypoSkin, WoundSkin, etc.) and skin derivatives (FrozenSkin, HistoSkin FFPE) through e-commerce shops for US, EU, and APAC markets. Products sold per model/unit with pricing varying by size, customization, and donor specifications.
2. Custom Non-Clinical Services: Tailored research services including non-clinical toxicity studies, local tolerance studies, inflammatory disease research, vaccine development, and topical/transdermal services. Services require 50% initiation payment and custom study plans.
3. Mast Cells and Culture Media: Sale of in vitro-derived mast cells (sold in increments of 1, 2, and 5 million cells per donor) and proprietary culture medium for maintaining skin models in culture.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Genoskin develops and sells standardized ex vivo human skin models derived from donated surgical tissue and provides custom contract research services using those models. Its products include the NativeSkin, HypoSkin, InflammaSkin, and WoundSkin platforms, alongside biological inputs (Human Mast Cells, HistoSkin FFPE sections, FrozenSkin) and analytical services spanning topical/transdermal testing, subcutaneous injection studies, vaccine immunoprofiling, local tolerance studies, spatial biology (Mantis), and bioinformatics. Customers are pharmaceutical, biotech, medical device, cosmetics, and chemicals companies seeking human-relevant preclinical testing that reduces reliance on animal models.

Product overview

Genoskin is a biotechnology CRO offering a comprehensive portfolio of ex vivo human skin platforms and related services for drug development, safety assessment, and dermatological research. The core product line includes NativeSkin® (live human skin models), NativeSkin access® (on-demand versions for in-house use), HypoSkin® (for injection testing), InflammaSkin® (psoriasis model), WoundSkin® (wounded skin model), and human mast cells. Supporting services encompass non-clinical toxicity testing (ISR Platform®, local tolerance studies), vaccine development, topical/transdermal services, spatial biology (Mantis platform), and bioinformatic analysis. The product ecosystem is complemented by skin derivatives including HistoSkin (FFPE slides/blocks), FrozenSkin, Culture Medium, FacialSkin, and HairSkin. Services can be ordered through regional e-shops (US, EU, APAC) or via custom study requests, with study initiation possible within 2 weeks.

Differentiator

Problem solved

Functional benefit

Brands

• NativeSkin: Ex vivo live human skin model platform for testing pharmaceutical, cosmetic and chemical products
• NativeSkin access
• HypoSkin
• InflammaSkin
• WoundSkin
• HairSkin
• FacialSkin
• FrozenSkin
• HistoSkin
• VaxSkin
• ISR Platform
• Mantis Platform

Products and services

• NativeSkin Standardized full-thickness ex vivo human skin model intended for pharmaceutical, biotech, cosmetics, and chemical industry customers conducting preclinical dermatology, toxicology, and efficacy studies without animal testing.
• NativeSkin access On-demand variant of NativeSkin offered through Genoskin's regional online shops, providing direct access to shipped skin models for independent customer testing.
• HypoSkin Ex vivo human skin model designed for subcutaneous injection testing, medical device injection training, and related preclinical applications.
• InflammaSkin Ex vivo skin model with induced psoriatic inflammation for pharmaceutical R&D customers researching psoriasis therapeutics and anti-inflammatory compounds.
• WoundSkin Ex vivo wounded skin model for medical device, dermatology, and wound care customers evaluating wound healing, tissue repair, and topical therapeutics.
• FacialSkin Ex vivo skin model sourced from facial donor tissue for cosmetics customers needing facial-specific skin testing of ingredients and finished products.
• HairSkin Ex vivo skin model with intact hair follicles for cosmetics and pharmaceutical customers researching hair biology, hair growth, and depilation products.
• HypoSkin Injection Training Service using HypoSkin models for hands-on training of subcutaneous injection techniques for medical device, aesthetics, and pharmaceutical customers.
• HypoSkin Virtual Expert Consultation Expert consultation service providing virtual guidance from Genoskin scientists on subcutaneous injection study design and interpretation.
• ISR Platform Standardized immunosafety assessment platform providing regulatory-grade data on topical, injectable, and biologic immunogenicity for pharmaceutical and biotech customers.
• Topical and Transdermal Testing Services Custom contract research service evaluating topical and transdermal drug delivery, skin penetration, and ingredient efficacy on ex vivo human skin.
• Vaccine Immunoprofiling Services Custom service profiling immune responses to vaccines and biologics using ex vivo human skin models for pharmaceutical and biotech customers.
• Local Tolerance Studies Custom contract research service evaluating local tolerance and biocompatibility of drugs, medical devices, and chemicals on ex vivo human skin.
• Spatial Biology Analysis (Mantis) Analytical service delivering high-resolution spatial tissue analysis on ex vivo human skin samples for pharmaceutical, biotech, and cosmetics customers.
• Bioinformatic Analysis Bioinformatics and data interpretation service supporting genomic, transcriptomic, and molecular readouts from Genoskin ex vivo skin studies.
• HistoSkin FFPE-preserved human skin sections sold as a biological input for histology, immunohistochemistry, and molecular analyses by external research customers.
• FrozenSkin Frozen human skin sections sold as a biological input for downstream molecular and histological analyses by research customers.
• Culture Medium Proprietary culture medium formulated to maintain ex vivo human skin viability, sold as a supporting product to skin model customers.
• Human Mast Cells Primary human mast cells sold as a standalone biological input for immunology, inflammation, and allergy research customers.

Quantifiable outcome

• 75% of leading top 20 large pharma companies have partnered with Genoskin
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• argenxcoreStrategic or Co-development Partner · 19 March 2026Collaboration presented at SOT Annual Meeting 2026 demonstrating HypoSkin ex vivo human skin platform successfully detects toxic control formulations for local tolerance screening. Study validates platform as translational human-based alternative to animal testing with demonstrated sensitivity and in vitro-in vivo correlation through macroscopic imaging and histopathology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MatTek Life Sciences: MatTek is the most directly comparable peer, producing standardized human skin tissue models (EpiDerm, EpiDermFT, MelanoDerm) used for in vitro dermatological, toxicity, and efficacy testing. It competes head-to-head with Genoskin's NativeSkin and HypoSkin in the same pharma/cosmetics customer base with similar OECD-validated test endpoints.
• Episkin (L'Oréal): Episkin, owned by L'Oréal, is a pioneer in reconstructed human epidermis models (EpiSkin, SkinEthic) for cosmetic and pharmaceutical safety testing. It is a direct competitor in reconstructed human skin models with deep scientific credibility and OECD validation, though its captive L'Oréal ownership limits commercial flexibility.
• Stratatech (Mallinckrodt): Stratatech, a Mallinckrodt company, develops human skin tissue models including StrataGraft for wound healing research. It overlaps with Genoskin's WoundSkin and InflammaSkin product lines in serving wound healing and dermatology research customers with human-relevant skin platforms.
• CellSystems Biotechnologie Vertrieb: CellSystems is a German distributor and developer of primary human cells and 3D tissue models including skin equivalents, serving the European research market. It competes with Genoskin in the EU distribution of skin models and related cell biology reagents.
• BioIVT: BioIVT is a major supplier of human biological specimens, including fresh and frozen human skin tissue for research and preclinical applications. It is a comparable tissue provider with overlapping customers in pharma/biotech preclinical research and similar sourcing infrastructure.

Broad incumbents

• Charles River Laboratories: Charles River is a global CRO offering broad preclinical safety, efficacy, and research services including skin and dermal toxicology studies. It is a broad incumbent that may compete or partner with Genoskin as pharma increasingly demands NAMs within larger integrated preclinical packages.
• Lonza Group: Lonza is a global CDMO and life science tools provider with cell and gene therapy manufacturing, including primary cells and tissue services. Its scale and Biologics 21st-century strategy position it as a potential partner or competitor for advanced NAM service offerings.
• Evotec SE: Evotec is a global drug discovery and development CRO offering preclinical, translational, and manufacturing services. Its Just-Evotec Biologicals and broader CRO platform overlap with Genoskin's drug development customer base and could expand into NAM-based preclinical offerings.

Emerging players

• CellGenix: CellGenix develops and manufactures cell culture reagents and GMP-grade cytokines for cell and gene therapy manufacturing. While focused on reagents rather than tissue models, it serves an overlapping translational research customer base that Genoskin's immunology and mast cell offerings also target.
• Crown Bioscience: Crown Bioscience offers preclinical CRO services including translational platforms for immuno-oncology and inflammation. Its ex vivo and in vitro service capabilities and pharma/biotech customer base overlap with Genoskin's positioning in immunology-driven preclinical research.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/genoskin

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genoskin